Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Tumor
100%
Mesothelioma
79%
Neoplasm
68%
Malignant Neoplasm
67%
Immunotherapy
62%
Cisplatin
58%
Tumor Microenvironment
55%
Immune Checkpoint Blockade
54%
Lymphocyte
41%
Tumor Immunity
32%
Tumor Cell
32%
Pleura Mesothelioma
31%
Treatment Response
28%
Dendritic Cell
26%
Polyinosinic Polycytidylic Acid
25%
Melanoma
25%
Antineoplastic Activity
24%
Cancer Chemotherapy
24%
Durvalumab
24%
Pleura Effusion
24%
Pemetrexed
23%
Immune Response
22%
Cancer Immunotherapy
21%
Biological Marker
20%
Cytotoxic T-Cell
20%
CTLA-4
20%
Arm
19%
Cancer
19%
Cancer Recurrence
18%
Clinical Study
18%
T Cell
17%
Overall Survival
17%
Cancer Cell
17%
Cytoreductive Surgery
16%
Debulking Surgery
16%
Diseases
16%
Clinical Trial
14%
Local Therapy
14%
Tumor Infiltrating Lymphocyte
14%
First-Line Chemotherapy
13%
Receptor
13%
Carboplatin
12%
Cancer Immunization
12%
STAT1 Protein
12%
Tretinoin
12%
Neoadjuvant Therapy
12%
Cyclophosphamide
12%
Soft Tissue Sarcoma
12%
Protein Tyrosine Kinase
12%
Dexamethasone
12%
Immunology and Microbiology
Immune Checkpoint Blockade
74%
Immunotherapy
62%
Cytotoxic T-Cell
59%
T Cell
40%
Cancer Immunotherapy
36%
Murine
35%
T Cell Receptor
33%
Interferon Type I
32%
Tumor Cell
32%
Tumor Antigen
31%
Dendritic Cell
30%
Pretreatment
26%
T-Helper Cell
25%
Cross-Presentation
24%
Cyclophosphamide
24%
Tumor Immunity
23%
Antigen Specificity
22%
Lymphocyte
21%
Immunocompetent Cell
20%
RNA Sequence
20%
Immune Response
19%
Tumor-Associated Macrophage
17%
CTLA-4
16%
Programmed Death-Ligand 1
16%
Peripheral Blood Lymphocyte
16%
Dexamethasone
15%
Gene Expression
14%
Tumor-Infiltrating Lymphocytes
14%
Regulatory T Cell
13%
Lymph Node
13%
Cell Population
13%
Maximum Tolerated Dose
13%
Mediator
12%
Neoantigen
12%
Sensitization
12%
Tumor Necrosis Factor Alpha
12%
Trastuzumab
12%
Transforming Growth Factor Beta
12%
STAT1
12%
Epithelial Mesenchymal Transition
12%
Xenograft
12%
Metabolite
12%
Tyrosine
12%
Immune System
12%
Immunotherapy Response
12%
Dynamics
12%
Cytotoxic T Cell
9%
CD8
9%
Peptides
8%
RNA Sequencing
8%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
96%
Mesothelioma
58%
Chemotherapy
56%
Cisplatin
43%
Neoplasm
42%
Pleura Mesothelioma
40%
Tumor Microenvironment
32%
Cytotoxic T Lymphocyte Antigen 4
30%
Polyinosinic Polycytidylic Acid
28%
Immunotherapy
26%
Durvalumab
24%
Retinoic Acid
24%
Peroxisome Proliferator Activated Receptor
24%
Receptor
17%
Cytotoxic Chemotherapy
16%
Dexamethasone
15%
CD8 Antigen
15%
Drug Discovery
14%
Biological Marker
13%
First-Line Chemotherapy
13%
Melanoma
13%
Interferon
13%
Toll Like Receptor 3
12%
Cancer Chemotherapy
12%
Cancer Recurrence
12%
Cyclophosphamide
12%
STAT1 Protein
12%
Pleura Effusion
12%
Geldanamycin
12%
Protein Tyrosine Kinase
12%
Trastuzumab
12%
Combination Drug
12%
Maximum Tolerated Dose
12%
STAT Protein
12%
Transforming Growth Factor Beta
12%
Esophageal Adenocarcinoma
12%
Toll Like Receptor Agonist
12%
Resiquimod
12%
Combination Therapy
12%
Pemetrexed
11%
Diseases
10%
Adverse Event
9%
Effusion
9%
Monotherapy
9%
Carboplatin
9%
Murine
8%
Cancer Model
8%
Chemoradiation Therapy
8%
Head and Neck Squamous Cell Carcinoma
8%
Clinical Trial
7%